Home » Stocks » Atara Biotherapeutics

Atara Biotherapeutics, Inc. (ATRA)

Stock Price: $12.73 USD 0.18 (1.43%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 911.28M
Revenue (ttm) n/a
Net Income (ttm) -301.36M
Shares Out 74.31M
EPS (ttm) -4.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $12.73
Previous Close $12.55
Change ($) 0.18
Change (%) 1.43%
Day's Open 12.50
Day's Range 12.35 - 13.04
Day's Volume 492,785
52-Week Range 4.52 - 19.36

More Stats

Market Cap 911.28M
Enterprise Value 576.79M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 74.31M
Float 54.50M
EPS (basic) -5
EPS (diluted) -4.98
FCF / Share -3.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 13.56M
Short Ratio 8.58
Short % of Float 23.20%
Beta 2.22
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.95
Revenue n/a
Operating Income -304.90M
Net Income -301.36M
Free Cash Flow -242.06M
Net Cash 334.49M
Net Cash / Share 4.67
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -54.27%
ROE -98.26%
ROIC -115.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 9
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$27.56*
(116.50% upside)
Low
8.00
Current: $12.73
High
70.00
Target: 27.56
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-296-237-122-81.24-58.45-28.16-8.62
Net Income-291-231-119-79.05-57.22-28.01-8.77
Shares Outstanding51.3143.8129.8628.7325.584.990.97
Earnings Per Share-5.67-5.27-4.00-2.75-2.24-5.62-9.08
Operating Cash Flow-236-180-87.50-60.03-37.16-16.63-5.97
Capital Expenditures-5.57-35.93-20.23-3.02-0.29-0.05-
Free Cash Flow-241-216-108-63.05-37.45-16.67-5.97
Cash & Equivalents25931016625632110451.62
Total Debt14.14------
Net Cash / Debt24531016625632110451.62
Assets34339221826432510651.83
Liabilities52.1652.9839.9210.189.882.941.75
Book Value291339178254315103-11.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Atara Biotherapeutics, Inc.
Country United States
Employees 409
CEO Pascal Touchon

Stock Information

Ticker Symbol ATRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATRA
IPO Date October 16, 2014

Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.